Kortikoide im Management des fortgeschrittenen Prostatakarzinoms

详细信息    查看全文

• 作者：Prof. Dr. H. Kübler
• 关键词：SchlüsselwörterProstatakarzinom ; metastasiertes ; Kastrationsresistenz ; Kortikosteroide ; Palliation ; Antitumoreffekte ; Abirateronacetat ; Chemotherapie
• 刊名：Der Urologe
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：56
• 期：2
• 页码：217-223
• 全文大小：
• 刊物类别：Medicine
• 刊物主题：Urology;
• 出版者：Springer Medizin
• ISSN：1433-0563
• 卷排序：56

文摘

Corticosteroids have been widely used for decades in cancer therapy, predominantly due to their anti-inflammatory activity. In the treatment of metastatic castration-resistant prostate cancer (mCRPC), corticosteroids play an important role both in the management of tumor-related symptoms, especially bone metastasis-related pain, and as concomitant treatment to counteract side effects associated with approved active prostatic anticancer agents such as docetaxel, cabazitaxel, and abiraterone acetate. In association with abiraterone acetate, low-dose corticosteroids (prednisone or prednisolone) reduce the mineralocorticoid side effects of abiraterone. In addition, corticosteroids may exert direct antitumoral activities, resulting in PSA decline.